The applicant asserted that the Axoguard HA+ Nerve Protector TM demonstrates clinical improvement in: (1) nerve health in an injured tissue bed through less adhesion, extraneural scarring, and inflammatory markers, (2) nerve health in an injured tissue bed through decreased friction between the nerve and surrounding tissue to allow for gliding and to minimize potential for soft tissue attachment, (3) device performance due to its sodium hyaluronate and sodium alginate gel layer that allows for nerve gliding, and (4) sensory and motor symptoms
(July 2002)
In one aspect, the one or more hepatocyte growth factor mimics is hexanoic-tyrosine- isoIeucine-(6)-amino-hexanoic amide
Oxidative stress, mitochondrial damage and neurodegenerative diseases
Differences among cell types in NAD + compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes
Both peptides have short half-lives (30 minutes for CJC without DAC, similar for ipamorelin), producing an acute GH pulse followed by return to baseline
